Statins are used to treat elevated levels of cholesterol and heart disease. They are among the most widely prescribed drugs in the world. A team of researchers, led by Elaine Tuomanen, at St. Jude Children's Research Hospital, Memphis, has now identified a potential new use for statins by studying a mouse model of sickle cell disease, the most common genetic disorder in the world.
Children with sickle cell disease have a much greater risk of developing an invasive infection with pneumococcal bacteria, something that is often lethal, that those that do not have the disease. In the study, when sickle cell–disease mice were treated with a statin before being infected with pneumococcal bacteria they lived for much longer than did infected, untreated sickle cell–disease mice. Further analysis identified two mechanisms underlying the protective effect of statins in this context: they reduced bacterial invasion into the blood system and they prevented cells being killed by the bacterial toxins. These data therefore suggest that prophylactic treatment with statins might reduce the susceptibility of children with sickle cell disease to invasive pneumococcal infection.
TITLE: Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease
AUTHOR CONTACT:
Elaine I. Tuomanen
St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Phone: (901) 595-3114; Fax: (901) 595-3099; E-mail: elaine.tuomanen@stjude.org .
View this article at: http://www.jci.org/articles/view/39843?key=4703d86cb370ef068f28
Journal of Clinical Investigation